ARC
AVEO

Absolute Return Capital’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Absolute Return Capital’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-36,290
Closed -$907K – 730
2013
Q2 		$907K Buy
+36,290
New +$1.55M 0.01% 621

Other funds holding AVEO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Absolute Return Capital's AVEO Position: Q3 2013 in Review

Absolute Return Capital sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2013, closing a stake of 36,290 shares — an estimated $907K sold.

Absolute Return Capital first reported a position in AVEO in Q2 2013 and held it in 1 quarter. The position peaked at $907K in Q2 2013. 81 funds tracked by Wall St. Rank hold AVEO as of Q3 2013.

  • Absolute Return Capital reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2013 after selling out during the quarter.
  • Absolute Return Capital sold 36,290 AVEO Pharmaceuticals, Inc. shares in Q3 2013, an estimated $907K.
  • Absolute Return Capital first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 1 quarter.
  • Absolute Return Capital's AVEO Pharmaceuticals, Inc. position peaked at $907K in Q2 2013.
  • 81 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2013.

Based on Absolute Return Capital's 13F filing for Q3 2013, filed 12 Nov 2013.